Your browser doesn't support javascript.
Veno-Arterial Extracorporeal Membrane Oxygenation for Circulatory Failure in COVID-19 Patients: Insights from the ECMOSARS Registry.
Anselmi, Amedeo; Mansour, Alexandre; Para, Marylou; Mongardon, Nicolas; Porto, Alizée; Guihaire, Julien; Morgant, Marie-Catherine; Pozzi, Matteo; Cholley, Bernard; Falcoz, Pierre-Emmanuel; Gaudard, Philippe; Lebreton, Guillaume; Labaste, François; Barbanti, Claudio; Fouquet, Olivier; Chocron, Sidney; Mottard, Nicolas; Esvan, Maxime; Fougerou-Leurent, Claire; Flecher, Erwan; Vincentelli, André; Nesseler, Nicolas.
  • Anselmi A; Department of Thoracic and Cardiovascular Surgery, Pontchaillou University Hospital, University of Rennes 1, Signal and Image Treatment Laboratory (LTSI), Inserm U1099, Rennes, France.
  • Mansour A; Department of Anesthesia and Critical Care, Pontchaillou, University Hospital of Rennes, France. Univ Rennes, CHU Rennes, Inserm, CIC 1414 (Centre d'Investigation Clinique de Rennes), F35000 Rennes, France. Univ Rennes, CHU de Rennes, Inra.
  • Para M; Department of Cardiovascular Surgery and Transplantation, Bichat Hospital, AP-HP, Paris, France; University of Paris, UMR 1148, Laboratory of Vascular Translational Science, Paris, France.
  • Mongardon N; Service d'anesthésie-réanimation, DMU CARE, DHU A-TVB, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, F-94010 Créteil, France. Univ Paris Est Créteil, Faculté de Santé, F-94010 Créteil, France. U955-IMRB, Equipe 03 « Pharmacologie et Technologies pour les Maladi
  • Porto A; Department of Cardiac Surgery, Timone Hospital, APHM, 13005, Marseille, France.
  • Guihaire J; Department of Cardiac Surgery, Inserm UMR_S 999, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Marie Lannelongue Hospital, Groupe Hospitalier Paris Saint Joseph, University of Paris-Saclay School of Medicine, Le Plessis Robinson, France.
  • Morgant MC; Department of Cardiovascular and Thoracic Surgery, Dijon University Hospital, 21000 Dijon, France.
  • Pozzi M; Department of Cardiac Surgery, "Louis Pradel" Cardiologic Hospital, 28 Avenue du Doyen Lépine, 69500 Lyon, France; Research on Healthcare Performance RESHAPE, INSERM U1290, Université Claude Bernard Lyon 1, 8 Avenue Rockefeller, 69008 Lyon, France.
  • Cholley B; AP-HP, Hôpital Européen Georges Pompidou, F-75015 Paris, France; Université de Paris, INSERM UMR_S 1140 "Innovations Thérapeutiques en Hémostase", F-75006 Paris, France.
  • Falcoz PE; INSERM, UMR 1260, Regenerative Nanomedicine (RNM), FMTS, 67000 Strasbourg. Université de Strasbourg, Faculté de médecine et pharmacie, 67000 Strasbourg. Hôpitaux Universitaire de Strasbourg, Service de chirurgie thoracique - Nouvel Hôpital Civil, Strasbourg, France.
  • Gaudard P; Department of Anesthesia and Critical Care, PhyMedExp, Montpellier University, INSERM, CNRS, CHU Montpellier, Montpellier, France.
  • Lebreton G; Sorbonne Université, INSERM, UMRS_1166-ICAN, Institute of Cardiometabolism and Nutrition, Paris, France. Service de Chirurgie Thoracique et Cardiovasculaire, Institut de Cardiologie, APHP, Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, France.
  • Labaste F; Anesthesiology and Intensive Care Department, CHU Toulouse, Toulouse, France. Institut des Maladies Métaboliques et Cardiovasculaires, INSERM U1048, Université de Toulouse, Université Paul Sabatier, Toulouse, France.
  • Barbanti C; APHP Necker, Paris University Hospital, Paris, France.
  • Fouquet O; Department of Thoracic and Cardiovascular Surgery, University Hospital, Angers, France. MITOVASC Institute CNRS UMR 6214, INSERM U1083, University of Angers, Angers, France.
  • Chocron S; Department of Thoracic and Cardiovascular Surgery, University of Franche-Comte, Besancon, France.
  • Mottard N; Department of Anesthesiology and Critical Care, Clinique de la Sauvegarde, RAMSAY Santé, Lyon, France.
  • Esvan M; Univ Rennes, CHU Rennes, Inserm, CIC 1414 (Centre d'Investigation Clinique de Rennes), F35000 Rennes, France.
  • Fougerou-Leurent C; Univ Rennes, CHU Rennes, Inserm, CIC 1414 (Centre d'Investigation Clinique de Rennes), F35000 Rennes, France.
  • Flecher E; Department of Thoracic and Cardiovascular Surgery, Pontchaillou University Hospital, University of Rennes 1, Signal and Image Treatment Laboratory (LTSI), Inserm U1099, Rennes, France.
  • Vincentelli A; Department of Cardiac Surgery, University Hospital of Lille, Lille, France.
  • Nesseler N; Department of Anesthesia and Critical Care, Pontchaillou, University Hospital of Rennes, France. Univ Rennes, CHU Rennes, Inserm, CIC 1414 (Centre d'Investigation Clinique de Rennes), F35000 Rennes, France. Univ Rennes, CHU de Rennes, Inra, Inserm, Institut NUMECAN - UMR_A 1341, UMR_S 1241, F-35000
Eur J Cardiothorac Surg ; 2023 Jun 06.
Article in English | MEDLINE | ID: covidwho-20232482
ABSTRACT

OBJECTIVES:

The clinical profile and outcomes of patients with Covid-19 who require veno-arterial or veno-venous-arterial extracorporeal membrane oxygenation (VA-ECMO - VAV-ECMO) are poorly understood. We aimed to describe the characteristics and outcomes of these patients and to identify predictors of both favorable and unfavorable outcomes.

METHODS:

ECMOSARS is a multicenter, prospective, nationwide French registry enrolling patients who require VV/VA-ECMO in the context of Covid-19 infection (652 patients at 41 centers). We focused on 47 patients supported with VA- or VAV-ECMO for refractory cardiogenic shock.

RESULTS:

Median age was 49. 14% of patients had a prior diagnosis of heart failure. The most common etiologies of cardiogenic shock were acute pulmonary embolism (30%), myocarditis (28%), and acute coronary syndrome (4%). E-CPR (Extracorporeal Cardiopulmonary Resuscitation) occurred in 38%. In-hospital survival was 28% in the whole cohort, and 43% when E-CPR patients were excluded. ECMO cannulation was associated with significant improvements in pH and FiO2 on day one, but non-survivors showed significantly more severe acidosis and higher FiO2 than survivors at this point (p = 0.030 and p = 0.006). Other factors associated with death were greater age (p = 0.02), higher BMI (p = 0.03), E-CPR (p = 0.001), non-myocarditis etiology (p = 0.02), higher serum lactates (p = 0.004), epinephrine (but not noradrenaline) use before initiation of ECMO (p = 0.003), hemorrhagic complications (p = 0.001), greater transfusion requirements (p = 0.001), and more severe SAVE and SAFE scores (p = 0.01 and p = 0.03).

CONCLUSIONS:

We report the largest focused analysis of VA- and VAV-ECMO recipients in Covid-19. Although relatively rare, the need for temporary mechanical circulatory support in these patients is associated with poor prognosis. However, VA-ECMO remains a viable solution to rescue carefully selected patients. We identified factors associated with poor prognosis and suggest that E-CPR is not a reasonable indication for VA-ECMO in this population.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Etiology study / Observational study / Prognostic study Language: English Journal subject: Cardiology Year: 2023 Document Type: Article Affiliation country: Ejcts

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Etiology study / Observational study / Prognostic study Language: English Journal subject: Cardiology Year: 2023 Document Type: Article Affiliation country: Ejcts